Colorado became the second US state to receive FDA approval to import prescription drugs from Canada after the agency authorized the state’s importation program on June 15, 2026.
The program has the potential to reduce drug prices by 20 to 70 percent and save Coloradans an estimated $46 million over three years
For more context, see our coverage of Florida Sues OpenAI Over ChatGPT Safety Claims.
Key Developments
through lower insurance premiums and out-of-pocket costs, according to the governor’s office.
The approval is a significant milestone for the drug importation movement, which has been legally authorized at the federal level since 2020 but has
faced implementation barriers that have prevented any state from actually importing drugs yet. Read also: Trump Approval Rating 36% Record Low on Economy.
Background and Context
For more context, see our coverage of Trump and Qatar Air Force One Deal.
Related Articles
Colorado is now second in line after Florida, which received approval before Colorado but has so far been unable to find Canadian suppliers willing to participate.
What Experts Are Saying
The two-year authorization permits Colorado to submit pre-import requests to the FDA for specific drug products.
The state must identify Canadian suppliers, verify the drugs meet US safety and labeling standards, and get FDA clearance for each product before importing.
For more context, see our coverage of Quantum Computing 2026 Where We Are.
See also: World Cup 2026 June 19: USA vs Australia, Brazil vs Haiti.
According to STAT News, Governor Jared Polis said the drugs could be available in Colorado as soon as next year if supplier arrangements can be secured.
The authorization does not guarantee any drugs will actually arrive; it creates the legal pathway for them to do so.
The 20 to 70 percent price reduction estimate is based on the difference between Canadian and US list prices for the same drugs.
Canadian prices are set by a government-mandated price review board; US prices are negotiated between manufacturers and pharmacy benefit managers, typically resulting in significantly higher list prices.
The critical unresolved challenge is finding Canadian pharmaceutical companies or distributors willing to sell to US state programs.
Florida, which received the first FDA approval in 2023, has been unable to import a single drug because Canadian pharmaceutical industry associations have strongly
opposed participation, arguing that large-scale exports to the US would reduce Canada’s own drug supply.
Health Canada has expressed concern that a surge in US demand for Canadian drugs would strain the Canadian supply chain and raise prices for Canadian patients.
Canadian manufacturers face pressure from their own government not to participate in programs that could disadvantage Canadian consumers.
Colorado may face the same barriers Florida has encountered.
The state’s strategy reportedly involves identifying specific drugs where Canadian supply is robust enough to accommodate export and where the price differential is large enough to justify the administrative cost.
State importation programs typically focus on high-cost maintenance medications, particularly insulin, asthma inhalers, HIV antiretrovirals, and certain cancer drugs, where Canadian prices are dramatically
lower and demand is predictable enough to plan supply chains.
Insulin is a consistent target. Canadian insulin prices are typically 80 to 90 percent lower than US prices for the same products.
Asthma inhalers run 70 to 80 percent cheaper. These categories offer the largest per-patient savings and represent the largest political argument for the program.
Drug importation from Canada has been debated in US policy for more than two decades.
Multiple bills authorizing it at the federal level were passed or blocked over that period.
The 2020 rule that created the state importation pathway was finalized under the first Trump administration and has survived subsequent changes in administration.
The policy question it raises, whether the US should allow market arbitrage to reduce drug prices rather than regulating prices directly, divides along predictable lines.
Free market advocates support importation as a market-based solution. Pharmaceutical industry groups argue it undermines the price structures that fund research and development.
Yes, the FDA approved Colorado’s drug importation program on June 15, 2026. The two-year authorization allows Colorado to submit pre-import requests for specific drugs from Canadian suppliers.
Drugs could be available in Colorado as soon as 2027 if the state can secure willing Canadian sellers, which remains the primary implementation challenge after Florida faced the same difficulty.
Canadian drug prices are typically 20 to 70 percent lower than US prices for the same medications, according to Colorado’s governor’s office.
For specific categories, the difference is larger: insulin is typically 80 to 90 percent cheaper in Canada, and asthma inhalers run 70 to 80 percent less.
The price differences reflect Canada’s government-mandated price review board versus the US negotiation-based pricing system.
Not yet as of June 2026.
Florida received the first FDA approval in 2023 but has been unable to import any drugs because Canadian pharmaceutical suppliers have declined to participate,
citing concerns about reducing Canada’s domestic drug supply.
Colorado is the second state to receive FDA authorization and faces the same supplier challenge.
Sources: CNBC – Economy | Reuters – Business | Bloomberg – Economics
Sources and Further Reading
Learn more at TechCrunch.
Learn more at The Verge.
Learn more at Wired.
Related Articles
Trust Post Desk
A journalist and editor at TrustPost.org covering world and national news, technology updates and human-interest stories. They check every fact, interview sources in person or online, and aim to deliver clear, accurate reporting. Their work ranges from breaking news to in-depth features and daily newsletters. Outside the newsroom, they follow emerging trends and engage with readers on social media.
